KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $3.2 million.

  • Pacira BioSciences' Non Operating Income rose 37123.7% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 12983.82%. This contributed to the annual value of -$373000.0 for FY2024, which is 10053.76% down from last year.
  • As of Q3 2025, Pacira BioSciences' Non Operating Income stood at $3.2 million, which was up 37123.7% from -$10.7 million recorded in Q2 2025.
  • Pacira BioSciences' Non Operating Income's 5-year high stood at $27.3 million during Q4 2022, with a 5-year trough of -$23.4 million in Q1 2023.
  • Over the past 5 years, Pacira BioSciences' median Non Operating Income value was -$6.7 million (recorded in 2021), while the average stood at -$2.4 million.
  • In the last 5 years, Pacira BioSciences' Non Operating Income plummeted by 33167.04% in 2021 and then skyrocketed by 146915.89% in 2025.
  • Pacira BioSciences' Non Operating Income (Quarter) stood at -$10.4 million in 2021, then soared by 361.88% to $27.3 million in 2022, then dropped by 3.37% to $26.3 million in 2023, then crashed by 137.27% to -$9.8 million in 2024, then soared by 132.21% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, -$10.7 million for Q2 2025, and $6.7 million during Q1 2025.